ClinicalTrials.Veeva

Menu

Extracorporeal Shockwave Therapy vs Mesotherapy in the Treatment of Myofascial Pain Syndrome: a Case-control Study

U

University of Palermo

Status

Completed

Conditions

Trigger Point Pain, Myofascial
Myofascial Pain Syndrome

Treatments

Other: Mesotherapy (Group B)
Other: Extracorporeal Shockwave Therapy (Group A)

Study type

Interventional

Funder types

Other

Identifiers

NCT06246591
MFR012024

Details and patient eligibility

About

Myofascial Pain Syndrome (MPS) is a disorder of the musculoskeletal system manifested by referred pain associated with functional limitation, muscle contractures, and possible neuralgic manifestations; this condition is characterized by the presence of "trigger points". The goal of this case-control study was to compare the effects and benefits of treatment with ESWT vs Mesotherapy in myofascial pain syndrome. The main question it aims to answer is: what is the best rehabilitation project-program between ESWT and mesotherapy for patients with myofascial syndrome? A case-control study was conducted at the U.O.C. of "Recovery and Functional Rehabilitation" A.O.U.P. "P. Giaccone" of Palermo from February 2022 to Dicember2023. Patients were randomized into 2 groups: in group "A", No. 5 sessions of focal ESWT were given weekly; in group "B", No. 5 sessions of Mesotherapy with administration of Thiocolchicoside fl 4mg/2ml and Mepivacaine fl 10mg/1ml were given weekly. Patients in group "A" and group "B" were evaluated at baseline (T0), after 5 sessions (T1) and one month after the end of treatment (T2). Researchers will compare patients treated with ESWT and patients performing mesotherapy to see if there are real differences in terms of pain reduction and improved quality of life.

Enrollment

54 patients

Sex

All

Ages

35 to 65 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Age 35-65 years
  • Diagnosis of myofascial syndrome
  • NRS at T0 ≥ 4
  • Written informed consent

Exclusion criteria

  • Pregnant patients
  • Patients with malignancies already diagnosed or in the process of diagnostic definition
  • Coagulation disorders and/or therapy with anticoagulants
  • Skin lesions and/or local infections
  • Contraindications and/or allergies to the active ingredients of Mesotherapy.

Trial design

Primary purpose

Treatment

Allocation

Randomized

Interventional model

Parallel Assignment

Masking

None (Open label)

54 participants in 2 patient groups

Extracorporeal Shockwave Therapy (Group A)
Active Comparator group
Description:
Patients of this group were invited to our department's outpatient clinics on a weekly basis, for a total of five sessions (5 weeks), lasting approximately 20 minutes each. Treatment energy and frequency were established following the recommendations and guidelines of the International Society for Medical Shockwave Treatment (ISMST).
Treatment:
Other: Extracorporeal Shockwave Therapy (Group A)
Mesotherapy (Group B)
Active Comparator group
Description:
Patients in this group underwent mesotherapy treatment at our outpatient clinics with Thiocolchicoside fl 4mg/2ml and Mepivacaine fl 10mg/1ml, once a week, for a total of five sessions (5 weeks), lasting about 15 minutes each.
Treatment:
Other: Mesotherapy (Group B)

Trial contacts and locations

1

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems